# Clinical Study of 18F-Alfatide Injection PET/CT

Source: https://onco.cc/trials/nct06416852/  
OnCo record `nct06416852` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Yantai LNC Biotechnology Singapore PTE. LTD., not yet recruiting.

## Summary

Clinical Study of 18F-Alfatide Injection PET/CT is a phase 3, interventional study registered as NCT06416852 by Yantai LNC Biotechnology Singapore PTE. LTD., with a registry enrolment figure of 428 participants, started 2024-08 and due to reach its primary completion in 2026-08. Interventions recorded: 18F-Alfatide Injection; 18F-FDG Injection. Conditions listed: Non-Small Cell Lung Cancer NSCLC. Primary outcome: Sensitivity and specificity evaluation of 18F-Alfatide Injection PET/CT compared with 18F-FDG PET/CT. Lung eligibility wording from the registry: "Patients with non-small cell lung cancer confirmed or highly suspected by investigators based on prior history, imaging, histopathology, and/or cytology, suspected lymph node metastasis and proposed radical surgery and lymph node dissection;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06416852
- Phase: 3
- Setting: A Multicenter, Open, Non-inferiority Phase III Clinical Study to Evaluate the Efficacy of 18F-Alfatide Injection PET/CT Compared With 18F-FDG PET/CT in the Diagnosis of Lymph Node Metastasis in Non-small Cell Lung Cancer
- Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD.
- Enrolled: 428

## Sources

- ClinicalTrials.gov NCT06416852: https://clinicaltrials.gov/study/NCT06416852

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06416852.json